Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Pharmaco-genomics Pharmaco-metabolomics Pharmaco-transcriptomics Pharmaco-proteomics Search

Displaying entries 59601 - 59625 of 102031 in total

Drug	Drug Groups	Gene	Gene ID	Change	Interaction	Chromosome	References
							Clear
Platelet Activating Factor	Experimental	PTGS1	5742	upregulated	Platelet Activating Factor results in increased expression of PTGS1 mRNA	9q33.2	A19846
Platelet Activating Factor	Experimental	PTGS2	5743	upregulated	Platelet Activating Factor results in increased expression of PTGS2 mRNA	1q31.1	A19846
Platelet Activating Factor	Experimental	SELE	6401	upregulated	Platelet Activating Factor results in increased expression of SELE mRNA	1q24.2	A19846
Platelet Activating Factor	Experimental	TIMP4	7079	upregulated	Platelet Activating Factor results in increased expression of TIMP4 mRNA	3p25.2	A19846
Platelet Activating Factor	Experimental	TNF	7124	upregulated	Platelet Activating Factor results in increased expression of TNF mRNA	6p21.33	A19846
Platinum	Investigational	CXCL8	3576	upregulated	Platinum analog results in increased expression of CXCL8 mRNA	4q13.3	A20617
Platinum	Investigational	GSTP1	2950	upregulated	[Acridine Orange binds to Platinum] which results in increased expression of GSTP1 mRNA	11q13.2	A23663
Plicamycin	Approved Withdrawn	F3	2152	downregulated	Plicamycin results in decreased expression of F3 mRNA	1p21.3	A23664
Plicamycin	Approved Withdrawn	TNIP1	10318	downregulated	Plicamycin results in decreased expression of TNIP1 mRNA	5q33.1	A23665
Vemurafenib	Approved Investigational	CCL2	6347	upregulated	PLX4032 results in increased expression of CCL2 mRNA	17q12	A23666
Vemurafenib	Approved Investigational	HIF1A	3091	upregulated	PLX4032 results in increased expression of HIF1A mRNA	14q23.2	A23666
Vemurafenib	Approved Investigational	MAGEA1	4100	downregulated	PLX4032 results in decreased expression of MAGEA1 mRNA	Xq28	A23667
Vemurafenib	Approved Investigational	MLANA	2315	upregulated	PLX4032 results in increased expression of MLANA mRNA	9p24.1	A23667
Vemurafenib	Approved Investigational	PMEL	6490	upregulated	PLX4032 results in increased expression of PMEL mRNA	12q13.2	A23667
Vemurafenib	Approved Investigational	TNFRSF10B	8795	upregulated	[KRAS protein mutant form affects the susceptibility to PLX4032] which results in increased expression of TNFRSF10B mRNA	8p21.3	A23668
Vemurafenib	Approved Investigational	TYR	7299	upregulated	PLX4032 results in increased expression of TYR mRNA	11q14.3	A23667
Polaprezinc	Investigational	IGF1	3479	upregulated	polaprezinc results in increased expression of IGF1 mRNA	12q23.2	A23669
Polydatin	Approved	CCL2	6347	downregulated	polydatin results in decreased expression of CCL2 mRNA	17q12	A20456 A20457
Polydatin	Approved	CXCL10	3627	downregulated	polydatin results in decreased expression of CXCL10 mRNA	4q21.1	A20456 A20457
Polydatin	Approved	CXCL8	3576	downregulated	polydatin results in decreased expression of CXCL8 mRNA	4q13.3	A20456 A20457
Polydatin	Approved	CYP1A1	1543	upregulated	polydatin results in increased expression of CYP1A1 mRNA	15q24.1	A20456
Polydatin	Approved	IL6	3569	downregulated	polydatin results in decreased expression of IL6 mRNA	7p15.3	A20456
Polydatin	Approved	TNF	7124	downregulated	polydatin results in decreased expression of TNF mRNA	6p21.33	A20456
Pomalidomide	Approved Investigational	CEBPA	1050	upregulated	pomalidomide results in increased expression of CEBPA mRNA	19q13.11	A23670
Pomalidomide	Approved Investigational	CEBPD	1052	upregulated	pomalidomide results in increased expression of CEBPD mRNA	8q11.21	A23670

Displaying entries 59601 - 59625 of 102031 in total

Pharmaco-transcriptomicsUp/down regulation of genes due to the metabolism of pharmaceutical compounds

Advanced Filter

Filter by Group

Filter by Market Availability